| Document |
Document Title |
|
WO/2002/067859A2 |
The invention relates to the use of ascorbic acid analogs as buffering reagents and chelating agents for the preparation of metalloradiopharmaceuticals. Also, invention relates to the use of ascorbic acid as a buffering reagent, a chelat...
|
|
WO/2002/067970A1 |
An isolated, water-soluble polypeptide derived from tryptophanyl-tRNA synthetase is useful for the inhibition of angiogenesis. The polypeptide consists essentially of the amino acid residue sequence SAKGIDYDKL IVRFGSSKID KELINRIERA TGQRP...
|
|
WO1999064055A9 |
Disclosed are multibinding compounds which are agonists, partial agonists, inverse agonists or antagonists of the 5HT4 receptors, which are involved in gastrointestinal disorders. The multibinding compounds of this invention containing f...
|
|
WO/2002/053700A2 |
The present invention provides epitopes present on cancer cells and important in physiological phenomena such as cell rolling, metastasis, and inflammation. Therapeutic and diagnostic methods and compositions using antibodies capable of ...
|
|
WO2000069900A9 |
A method for protecting a peptide from peptidase activity in vivo , the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is describe...
|
|
WO/2002/040060A2 |
The invention provides radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods of making such radiopharmaceuticals, ligands, and intermedi...
|
|
WO/2002/030990A1 |
The present invention relates to water-insoluble, crosslinked amide derivatives of hyaluronic acid and manufacturing method thereof, where the amide derivatives of hyaluronic acid are characterized by crosslinking, of polymer or oligomer...
|
|
WO/2002/030987A1 |
A monoclonal antibody showing no cross reactivity with a stress non-induced enzyme human HO (heme oxygenase)-2 but enabling specific detection of stress-induced human HO-1 and thus being capable of inhibiting the human HO-1 activity; a m...
|
|
WO/2002/019822A1 |
The present invention relates to cationic and polycationic compositions and methods for enhancing synthesis of nucleic acid molecules. In a preferred aspect, the invention relates to inhibition or control of nucleic acid synthesis, seque...
|
|
WO/2002/012275A2 |
The invention relates to novel peptides and their use in assays for identifying novel immunosuppressants. More particularly the present invention provides methods and compositions for identifying compounds that will modulate the interact...
|
|
WO2001025794B1 |
Protein molecules (4a-4c, 10, 10a-10c) of interest are isolated and modified into linearized protein molecules (10, 10a-10c). Individual protein molecules are isolated for observation with hydrodynamic focusing apparatus (130), atomic fo...
|
|
WO/2002/008449A2 |
The invention relates to an improved method for predicting the onset of, diagnosing, prognosticating and/or treating dementing diseases. The method comprises determining the level of heme oxygenase-1 suppressor (HOS) activity and/or fact...
|
|
WO/2002/006306A2 |
The present invention is directed to novel substrates for Hu-Asp. More particularly, the invention provides peptide substrates and fusion polypeptide substrates comprising a $g(b)-secretase cleavage site. Methods and compositions for mak...
|
|
WO/2002/004014A1 |
The invention relates to a bioactive chemical composition, more specifically to proteins and can be used in medicine, veterinary and cell biology. The inventive glycoproteins are extracted from an intercellular space of the tissue of var...
|
|
WO/2001/098522A2 |
The present invention relates to novel types of peptide nucleic acids (PNAs) with improved properties. In particular, it relates to positively charged PNA units having an ethylene linker between the backbone and the nucleobase, to oligon...
|
|
WO/2001/094327A1 |
There is provided a process for the addition of a nucleophile across an electron poor carbon-carbon double bond (a Michael addition) comprising contacting in a solvent: i) a nucleophile; ii) a compound comprising an electron poor double ...
|
|
WO/2001/086590A1 |
The present invention relates to the fields of biology and computer sciences. The present invention provides proteinaceous molecules to encode solutions to computational problems. In one aspect the invention provides the use of a protein...
|
|
WO/2001/083507A1 |
The present invention provides efficient methods for identifying nucleic acid molecules and polypeptides encoded thereby. These methods can be performed using transcription and translation systems or methods, or using translation methods...
|
|
WO2000047775A9 |
Described herein are RNA-protein fusion production methods which involve a high salt post-translational incubation step.
|
|
WO/2001/074898A2 |
Charged compounds are provided that comprise one or more regions of localized positive charge, compositions comprising such compounds, methods of synthesizing such compounds, methods of screening such compounds to identify those having a...
|
|
WO/2001/068673A1 |
The present invention relates generally to oligonucleotide analogues that include novel protein nucleic acid molecules (PNAs), particularly monomers, dimers, oligomers thereof and methods of making and using these oligonucleotide analogu...
|
|
WO/2001/057066A2 |
The invention relates to a method of stabilizing a hydrophobin-containing solution. According to the present invention, the hydrophobin is subjected to a treatment with a disulphide bridge-cleaving agent to yield unfolded hydrophobin, sa...
|
|
WO/2001/051011A2 |
Disclosed are condensation products of proteins and/or protein hydrolysates, whereby azelaic acid is used.
|
|
WO1999064045A9 |
Disclosed are multibinding compounds that bind cell membrane transporters and modulate their activity. The multibinding compounds contain from 2 to 10 ligands covalently attached to one or more linkers.
|
|
WO1999063937A9 |
Disclosed are multibinding compounds which include macrolide antibiotics, aminoglycosides, lincosamides, oxazolidinones, streptogramins, tetracycline and/or other compounds which bind to bacterial ribosomal RNA and/or to one or more prot...
|
|
WO1999064041A9 |
Disclosed are novel multi-binding compounds (agents) which bind to NMDA receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors, thereby modulating the biological processes and/...
|
|
WO/2001/014411A1 |
A method is provided of producing an immunogenic complex comprising a heat shock protein (hsp) coupled to a heterologous antigenic polypeptide, which method comprises: (a) expressing the antigenic polypeptide in a cell which cell has bee...
|
|
WO1999064049A9 |
This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligan...
|
|
WO/2001/004316A2 |
WO99/36544 discloses a large number of proteins from Neisseria Meningitidis. The present invention relates to fragments of those proteins which comprise at least one antigenic determinant. Homologous sequences and proteins comprising the...
|
|
WO/2000/074701A2 |
Cardiovascular cell proliferation in a blood vessel subjected to trauma, such as angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 ami...
|
|
WO/2000/065060A2 |
The invention relates to identifying and characterising a grass-pollen allergen and a recombinant DNA molecule which can be coded therefor and to corresponding DNA and peptide sequences.
|
|
WO/2000/061813A1 |
A new protein named Tankyrase II is described in this disclosure. Sequences for the human Tankyrase II cDNA and the protein translation product are provided. Also provided are species homologs, muteins, related nucleic acids, peptides, a...
|
|
WO1999064039A9 |
Disclosed are multibinding compounds which are bradykinin antagonists. The multibinding compounds of this invention contain from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a b...
|
|
WO/2000/058405A2 |
Compounds having the structure: W = Sq - A where A has the formula: -NR?1¿R?2¿, where R?1¿ and R?2¿ are the same or different and each is H or C¿1?-C¿20? hydrocarbon or a group -L-G, or one of R?1¿ and R?2¿ is -OR?5¿ or -NR?6¿R...
|
|
WO/2000/053749A2 |
The invention relates to new polypeptide in isolated form belonging to a subfamily of the human Immunoglobulin Superfamily, which polypeptide shows at least 70 % sequence homology with the amino acid sequence of the murine Confluency Reg...
|
|
WO1999063936A9 |
Novel multi-binding compounds (agents) which bind endothelin receptors are used to treat disorders affecting the cardiovascular, renal, endocrine and nervous systems in mammals that are mediated by the endothelin receptors, such as conge...
|
|
WO1999064033A9 |
This invention relates to novel multibinding compounds that bind to the enzyme phosphodiesterase V (PDE V) and modulate its activity. The compounds of this invention comprise 2-10 PDE V modulator (particularly inhibitor) ligands covalent...
|
|
WO1999066944A9 |
Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological proce...
|
|
WO1999064048A9 |
Disclosed are multibinding compounds which inhibit the enzyme HIV reverse transcriptase, an enzyme which catalyzes the conversion of viral RNA to single stranded DNA. The multibinding compounds of this invention containing from 2 to 10 l...
|
|
WO/2000/040700A2 |
The invention provides a microinsertion-based, trans-complementation method of $i(in vitro) oocyte activation useful to identify properties of sperm-borne oocyte-activating factor(s) (SOAF) and ooplasmic interactions with sperm component...
|
|
WO/2000/040712A1 |
The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; (b) expressing the geneti...
|
|
WO1999064035A9 |
Disclosed are multibinding compounds which are beta 2-adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system...
|
|
WO1999064034A9 |
The present invention is directed to multibinding compounds which are beta 2 adrenergic receptor agonists and are therefore useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis, and the like. They are...
|
|
WO/2000/036136A1 |
Metallopeptide combinatorial libraries and methods of making libraries and metallopeptides are provided for use in biological, pharmaceutical and related applications. The combinatorial libraries are made of peptides, peptidomimetics and...
|
|
WO/2000/034462A1 |
Human/human hybrid cells were made via fusion of human embryonic kidney cells (293S) and modified Burkitt's lymphoma cells (2B8). The fusion cells are useful as host cells for the recombinant expression of mammalian genes. The advantages...
|
|
WO/2000/034236A1 |
The present invention provides lipidized conjugates comprising an amino group-containing biologically active substance and a lipophilic group capable of penetrating a biological membrane. Under neutral or mildly acidic conditions, includ...
|
|
WO/2000/030618A1 |
The invention concerns delivery particles (DP's) for active principles (AP's) based on linear amphiphilic polyamino-acids (PAA's), with $g(a)-peptide chains, capable of being spontaneously formed by contacting PAA's with a liquid medium,...
|
|
WO/2000/029620A1 |
A method of facilitating vascular growth in a subject in need of such treatment comprises inhibiting EMAP II activity in the subject by an amount effective to stimulate vascular growth in the subject (e.g., in the lungs or heart of the s...
|
|
WO1999064038A9 |
Novel multibinding compounds are disclosed. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to an nAChR receptor, thereby modulating the biological processes/f...
|
|
WO1999063988A9 |
Disclosed are multibinding compounds which inhibit nitric oxide synthases (NOSs), enzymes which form nitric oxide and L-citrulline from L-arginine. The multibinding compounds of this invention contain from 2 to 10 ligands covalently atta...
|
